A heart-wrenching campaign is unfolding in Parliament as a widow, Ellie James, seeks to change the treatment landscape for brain tumor patients—a cause she feels compelled to champion following the tragic death of her husband, Owain, who passed away at just 34 years old. This dedicated 36-year-old mother from Caerphilly believes that she cannot resume her normal life until significant changes are made in how hospitals handle brain tumor tissue after surgical procedures.
Ellie's campaign aims to implement "Owain's Law," which would mandate all hospitals to preserve brain tumor tissue removed during surgery for potential future use in vaccines or medical research. The issue is slated for discussion among MPs in an upcoming parliamentary debate, where Ellie hopes to inspire action across the UK.
Reflecting on her husband's experience, Ellie shared that Owain had expressed a desire for his struggles to lead to improvements in treatment options for others. Unfortunately, he had limited access to an immunotherapy vaccine because only a small portion of his tumor tissue was preserved for future use. Despite undergoing a surgery that successfully removed half of his malignant stage four tumor, doctors indicated that they could only manage the remaining part temporarily.
After his surgery, the couple opted for an immunotherapy vaccine that was not available through the NHS, which utilized the very tumor tissue that had been extracted. However, out of the 7 centimeters of tumor that was removed, merely 1 centimeter was frozen and deemed usable. Remarkably, this treatment caused the remaining tumor to fully regress. Sadly, nine months later, another tumor resurfaced, leading to Owain's death in June 2024.
Ellie firmly believes that if more of her husband's tumor tissue had been preserved, they could have produced additional vaccine doses, potentially extending his life: "If we had been able to freeze more tissue, I truly believe he would still be here today."
She envisions her late husband being immensely proud of any legislative changes that arise from his story, particularly those ensuring that patients provide explicit consent before their tissue is removed and that all surgical tissue remains the property of the patient, automatically designated for freezing. She emphasized, "If we had been properly informed, we would have chosen to freeze the tissue, but that choice was taken out of our hands."
In a poignant example of the necessity for such changes, another patient named Matt Collins, who is battling glioblastoma—the most aggressive form of brain tumor—described how Owain's Law might have significantly benefitted him in his fight against the disease. Diagnosed in October 2023 after suffering a stroke, Matt underwent a lengthy operation to eliminate a tumor the size of a golf ball. However, by July, he learned that his tumor had begun to regrow.
Through fundraising efforts, Matt managed to raise £100,000 for a non-NHS treatment called DcVax-L, a personalized vaccine made from his own tumor cells. Unfortunately, due to improper storage of his tumor tissue post-operation, he only received four doses of the treatment instead of the ten he had anticipated. "It wouldn't have cured my cancer, but it could have given me a couple more months," he lamented, noting that he has been given a prognosis of 12 to 18 months to live. He added, "It's vital that tissue is stored correctly and that patients are aware of their options. I was never informed about the availability of a vaccine."
The charity Brain Tumor Research has echoed these sentiments, advocating for enhanced capacity for frozen tissue storage throughout the UK. Dr. Karen Noble, their director of research, policy, and innovation, stated, "Personalized treatments for brain tumors depend on gathering comprehensive genetic information shortly after surgery. The manner in which tissue is preserved post-surgery is crucial since there’s a genuine risk of losing critical data, which can impede access to clinical trials and innovative therapies."
In response to the campaign, the Welsh government commented that the need for new legislation has not been sufficiently demonstrated. A spokesperson articulated that healthcare professionals already utilize their expertise to balance diagnostic requirements with opportunities for research and novel treatments. They cautioned that imposing legislation could compromise timely diagnoses or lead to conflicts when tissue volumes are limited, assuring that they would collaborate with relevant organizations to prioritize the best interests of patients regarding tissue archiving and genomic testing.
On a broader scale, the UK's Department of Health and Social Care (DHSC) reinforced the importance of innovative research in combating brain cancer, announcing a £13.7 million investment aimed at supporting cutting-edge studies that could yield new treatment options for patients.
